Benitec Biopharma ROE 2014-2022 | BNTC

Current and historical return on equity (ROE) values for Benitec Biopharma (BNTC) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Benitec Biopharma ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-09-30 $-0.02B $0.02B -194.59%
2022-06-30 $-0.02B $0.00B -194.59%
2022-03-31 $-0.02B $0.01B -125.93%
2021-12-31 $-0.02B $0.01B -126.32%
2021-09-30 $-0.02B $0.02B -104.92%
2021-06-30 $-0.01B $0.02B -103.70%
2021-03-31 $-0.01B $0.01B -118.18%
2020-12-31 $-0.01B $0.02B -133.33%
2020-06-30 $-0.01B $0.01B -96.00%
2020-03-31 $-0.01B -66.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00